Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

Presentation ESC 2016

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

Presenter: Raban V. Jeger

August 31, 2016

News Conference News ESC 2016

BASKET-SAVAGE: DES Reign for Saphenous Vein Graft PCI Amid Declining Use

Shelley Wood

August 31, 2016

News Conference News ESC 2016

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

Shelley Wood

August 30, 2016

News Conference News ESC 2016

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

Michael O'Riordan

August 28, 2016

Presentation ESC 2016

NIPPON Randomized Study: 6 Months vs 18 Months Dual Antiplatelet Treatment For Patients Underwent Bioabsorbable Polymer And Abluminal Coated DES Deployment

Presenter: Masato Nakamura

August 28, 2016

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

Presentation ESC 2015

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Presenter: Takeshi Kimura

September 01, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

News Conference News ESC 2014

PROTECT: ZES Sustain Lead Over SES at 5 Years

Caitlin E. Cox

September 03, 2014

Presentation ESC 2014

Randomised comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for percutaneous coronary revascularization

Presenter: Thomas Pilgrim

September 01, 2014

News Conference News ESC 2014

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Yael L. Maxwell

September 01, 2014

Presentation ESC 2014

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

Presenter: Christoph Varenhorst

August 30, 2014

News Conference News ESC 2014

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

Todd Neale

August 30, 2014

News Conference News ESC 2012

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Caitlin E. Cox

August 29, 2012

News Conference News ESC 2012

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

August 27, 2012

Presentation ESC 2012

Patient Related Outcomes with Endeavor Versus Cypher Stenting Trial

Presenter: William Wijns

August 27, 2012

News Conference News ESC 2012

Survey Reveals Improvements, Gaps in Primary PCI Access Across Europe

Jason Kahn

August 26, 2012

News Conference News

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

September 02, 2011

News Conference News

Landmark Analyses Show Downside of Prolonged Antiplatelet Therapy

September 02, 2011

Advertisement

Drug-Eluting vs Bare Metal Stents in Saphenous Vein Grafts: The Prospective Randomized BASKET-SAVAGE Trial

BASKET-SAVAGE: DES Reign for Saphenous Vein Graft PCI Amid Declining Use

NORSTENT: Do Modern-day Bare-Metal Stents Stand Up to Drug-Eluting Stents?

NIPPON: With Nobori Stent, 6 Months of DAPT as Safe and Effective as 18 Months

NIPPON Randomized Study: 6 Months vs 18 Months Dual Antiplatelet Treatment For Patients Underwent Bioabsorbable Polymer And Abluminal Coated DES Deployment

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

PROTECT: ZES Sustain Lead Over SES at 5 Years

Randomised comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for percutaneous coronary revascularization

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents

SCAAR Confirms Low Very Late Stent Thrombosis Risk with Newer DES

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

Patient Related Outcomes with Endeavor Versus Cypher Stenting Trial

Survey Reveals Improvements, Gaps in Primary PCI Access Across Europe

Two Trials Show Favorable Results with XIENCE V vs. Earlier DES, BMS

Landmark Analyses Show Downside of Prolonged Antiplatelet Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content